Page 1754 - Williams Hematology ( PDFDrive )

1728 Part XI: Malignant Lymphoid Diseases Chapter 106: Essential Monoclonal Gammopathy 1729

99. Leung N, Bridoux F, Hutchison CA, et al: Monoclonal gammopathy of renal signifi- 133. Niermeijer JM, Eurelings M, Lokhorst H, et al: Neurologic and hematologic response to
cance: When MGUS is no longer undetermined or insignificant. Blood 120:4292, 2012. fludarabine treatment in IgM MGUS polyneuropathy. Neurology 67:2076, 2006.
100. Sethi S, Rajkumar SV: Monoclonal gammopathy-associated proliferative glomerulone- 134. Finsterer J: Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol
phritis. Mayo Clin Proc 88:1284, 2013. Scand 112:115, 2005.
101. Fermand JP, Bridoux F, Kyle RA, et al: How I treat monoclonal gammopathy of renal 135. Renaud S, Fuhr P, Gregor M, et al: High-dose rituximab and anti-MAG-associated
significance (MGRS). Blood 122:3583, 2013. polyneuropathy. Neurology 66:742, 2006.
102. Paladini I, Pieretti G, Giuntoli M, et al: Crystalline corneal deposits in monoclonal 136. Kristinsson SY, Fears TR, Gridley G, et al: Deep vein thrombosis following monoclo-
gammopathy: In-vivo confocal microscopy. Semin Ophthalmol 28:37, 2013. nal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood
103. Secundo W, Seifert P: Monoclonal corneal gammopathy: Topographic considerations. 112:3582, 2008.
Ger J Ophthalmol 5:262, 1996. 137. Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW: Prothrombotic coagulation abnor-
104. Shah S, Espana EM, Margo CE: Ocular manifestations of monoclonal copper-binding malities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Mye-
immunoglobulin. Surv Ophthalmol 59:11, 2014. loma 7:462, 2007.
105. Probst LE, Hoffman E, Cherian MG, et al: Ocular copper deposition associated with 138. Melton LJ 3rd, Rajkumar SV, Khosla S, et al: Fracture risk in monoclonal gammopathy
benign monoclonal gammopathy and hypercupremia. Cornea 15:94, 1996. of undetermined significance. J Bone Miner Res 19:25, 2004.
106. Saffra N, Rakhamimov A, Solomon WB, Scheers-Masters J: Monoclonal gammopathy 139. Farr JN, Zhang W, Kumar SK, et al: Altered cortical microarchitecture in patients with
of undetermined significance maculopathy. Can J Ophthalmol 48:e168, 2013. monoclonal gammopathy of undetermined significance. Blood 123:647, 2014.
107. Drappatz J, Batchelor T: Neurologic complications of plasma cell disorders. Clin Lym- 140. Burner E, Swahlen A, Cruchaud A: Nonmalignant monoclonal immunoglobulinemia,
phoma 5:163, 2004. pernicious anemia, and gastric carcinoma: A model of immunologic dysfunction. Am J
108. Lozeron P, Adams D: Monoclonal gammopathy and neuropathy. Curr Opin Neurol Med 60:1019, 1976.
20:536, 2007. 141. Rowland LP, Osserman EF, Scharfman WB, et al: Myasthenia gravis with a myeloma-
109. Ropper AH, Gorsin KC: Neuropathies associated with paraproteinemia. N Engl J Med type gamma-G (IgG) immunoglobulin abnormality. Am J Med 46:599, 1969.
338:1601, 1998. 142. Ilfeld D, Barzilay J, Vana D, et al: IgG monoclonal gammopathy in four patients with
110. Kissel JT, Mendell JR: Neuropathies associated with monoclonal gammopathies. Neuro- polymyalgia rheumatica [letter]. Ann Rheum Dis 44:501, 1985.
muscul Disord 6:3, 1996. 143. Nanji AA: Monoclonal gammopathy associated with Crohn’s disease during treatment
111. Vallatt JM, Jauberteau MO, Bordessoule D, et al: Link between peripheral neuropathy with total parenteral nutrition. JPEN J Parenter Enteral Nutr 9:621, 1985.
and monoclonal dysglobulinemia: A study of 66 cases. J Neurol Sci 137:124, 1996. 144. Wallach D, Carado Y, Foldes C, Cottennot F: Dermatomyositis and monoclonal gam-
112. Lee KW, Inghirami G, Spatz L, et al: The B-cells that express anti-MAG antibodies in mopathy. Ann Dermatol Venereol 112:783, 1985.
neuropathy and non-malignant IgM monoclonal gammopathy belong to the CD5 sub- 145. McFadden N, Ree K, Syland E, Larse TE: Scleredema adultorum associated with a
population. J Neuroimmunol 31:83, 1991. monoclonal gammopathy and generalized hyperpigmentation. Arch Dermatol 123:629,
113. Cocito D, Durelli L, Isoardo G: Different clinical, electrophysiological and immunological 1987.
features of CDIP associated with paraproteinemia. Acta Neurol Scand 108:274, 2003. 146. Oikarinen A, Ala-Kokko L, Palatsi R, et al: Scleroderma and paraproteinemia. Arch
114. Chassande B, Léger J-M, Younes-Chennoufi AB, et al: Peripheral neuropathy associated Dermatol 123:226, 1987.
with IgM monoclonal gammopathy: Correlation between M-protein antibody activity 147. Johnsson V, Svendsen B, Vostrup S, et al: Multiple autoimmune manifestations in
and clinical/electrophysiological features in 40 cases. Muscle Nerve 21:55, 1998. monoclonal gammopathy of undetermined significance and chronic lymphocytic leu-
115. Pestronk A, Li F, Bieser BS, et al: Anti-MAG antibodies. Neurology 44:1131, 1994. kemia. Leukemia 10:327, 1996.
116. Stubbs EB Jr, Lawlor MW, Richards MP, et al: Anti-neurofilament antibodies in neurop- 148. Kyle RA: Monoclonal gammopathy of unknown significance (MGUS). Baillieres Clin
athy with monoclonal gammopathy of undetermined significance produce experimen- Haematol 8:761, 1995.
tal motor nerve conduction block. Acta Neuropathol 105:109, 2003. 149. Kagaya M, Takahashi H: A case of type I cryoglobulinemia associated with a monoclo-
117. Ellie E, Vital A, Steck A, et al: Neuropathy associated with “benign” anti-myelin- nal gammopathy of undetermined significance (MGUS). J Dermatol 32:128, 2005.
associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiologi- 150. de Koning HD, Bodar EJ, van der Meer JW, et al: Schnitzler syndrome: Beyond the
cal pathological findings and response to treatment in 33 cases. J Neurol 243:34, 1996. case reports: Review and follow-up of 94 patients with an emphasis on prognosis and
118. Di Troia A, Carpo M, Meucci N, et al: Clinical features and anti-neural reactivity in treatment. Semin Arthritis Rheum 37:137, 2007.
neuropathy associated with IgG monoclonal gammopathy of undetermined signifi- 151. Ryan JG, de Koning HD, Beck LA, et al: IL-1 blockade in Schnitzler syndrome: Ex vivo
cance. J Neurol Sci 164:64, 1999. findings correlate with clinical remission. J Allergy Clin Immunol 121:260, 2008.
119. Vallat JM, Magy L, Richard L, Piaser M, et al: Intranervous immunoglobulin deposits: 152. Wayte JA, Rogers S, Powell FC: Pyoderma gangrenosum, erythema elevatum diutinum
An underestimated mechanism of neuropathy. Muscle Nerve 38:904, 2008. and Ig A monoclonal gammopathy. Australas J Dermatol 36:21, 1995.
120. Gorsin KC, Ropper AH: Axonal neuropathy associated with monoclonal gammopathy 153. Doutre MS, Beylot C, Bioulac P, Bezian JH: Monoclonal IgM and chronic urticaria: Two
of undetermined significance. J Neurol Neurosurg Psychiatry 63:163, 1997. cases. Ann Allergy 58:413, 1987.
121. Wilson JR, Stittsworth JD Jr, Fisher MA: Electrodiagnostic patterns in MGUS neurop- 154. Samochocki Z, Szudzinski A: Gangrenous pyoderma in monoclonal IgA gammopathy
athy. Electromyogr Clin Neurophysiol 41:409, 2001. and functional disorders of T lymphocytes. Przegl Dermatol 73:409, 1986.
122. Nicholas G, Maisonobe T, Le Forestier N, et al: Proposed revised electrophysiologi- 155. Abraham Z, Feuerman EJ: IgA benign monoclonal gammopathy with recurrent
cal criteria for chronic inflammatory demyelinating polyradiculopathy. Muscle Nerve self-healing skin tumors. J Am Acad Dermatol 21:1303, 1989.
25:26, 2002. 156. Paul C, Fermaud J-P, Flageul B, et al: Hyperkeratotic spicules and monoclonal gammo-
123. Jonsson V, Schroder HD, Trojaborg W, et al: Autoimmune reactions in patients with pathy. J Am Acad Dermatol 33:346, 1995.
M-component and peripheral neuropathy. J Intern Med 232:185, 1992. 157. Scutellari PN, Antinolfi G: Association between monoclonal gammopathy of undeter-
124. Gorsin KC, Allan G, Ropper AH: Chronic inflammatory demyelinating polyneurop- mined significance (MGUS) and diffuse idiopathic skeletal hyperostosis (DISH). Radiol
athy: Clinical features and response to treatment in 67 consecutive patients with and Med (Torino) 108:172, 2004.
without a monoclonal gammopathy. Neurology 48:321, 1997. 158. Schnur MJ, Appel GB, Bilezikian JP: Primary hyperparathyroidism and benign mono-
125. Vital A, Nedelec-Ciceri C, Vital C: Presence of crystalline inclusions in the peripheral clonal gammopathy. Arch Intern Med 137:1201, 1977.
nerve of a patient with IgA lambda monoclonal gammopathy of undetermined signifi- 159. Rao DS, Antonelli R, Kane KR, et al: Primary hyperparathyroidism and monoclonal
cance. Neuropathology 28:526, 2008. gammopathy. Henry Ford Hosp Med J 39:41, 1991.
126. Latov N: Pathogenesis and therapy of neuropathies associated with monoclonal gam- 160. Schoenfeld Y, Berliner S, Pinkhas J, Beutler E: The association of Gaucher’s disease and
mopathies. Ann Neurol 37(Suppl 1):532, 1995. dysproteinemias. Acta Haematol 64:241, 1980.
127. Sghirlanzoni A, Solari A, Ciano C: Chronic inflammatory demyelinating polyradicul- 161. de Fost M, Out TA, de Wilde FA, et al: Immunoglobulin and free light chain abnormal-
opathy: Long-term course and treatment of 60 patients. Neurol Sci 21:31, 2000. ities in Gaucher disease type I: Data from an adult cohort of 63 patients and review of
128. Kiprov DD, Miller RG: Paraproteinemia associated with demyelinating polyneuropa- the literature. Ann Hematol 87:439, 2008.
thy or myositis: Treatment with plasmapheresis and immunosuppressive drugs. Artif 162. Rodic P, Pavlovic S, Kostic T et al: Gammopathy and B lymphocyte clonality in patients
Organs 9:47, 1985. with Gaucher type I disease. Blood Cells Mol Dis 50:222, 2013.
129. Gorson KC: Clinical features, evaluation, and treatment of patients with polyneuropa- 163. Andreone P, Zignego AL, Cursaro C, et al: Prevalence of monoclonal gammopathies in
thy associated with monoclonal gammopathy of undetermined significance (MGUS). J patients with hepatitis C virus infection. Ann Intern Med 129:294, 1998.
Clin Apher 14:149, 1999. 164. Hamazaaki K, Baba M, Hasegawa H, et al: Chronic hepatitis associated with mono-
130. Blume G, Pestronk A, Goodnough LT: Anti-MAG antibody-associated polyneuropa- clonal gammopathy of undetermined significance. Gastroenterol Hepatol 18:459,
thies: Improvement following immunotherapy with monthly plasma exchange and IV 2003.
cyclophosphamide. Neurology 45:1577, 1995. 165. Schafer AL, Miller JB, Lester EP, et al: Monoclonal gammopathy in hereditary sphero-
131. Oksenhendler E, Chevret S, Léger JM, et al: Plasma exchange and chlorambucil in cytosis: A possible pathogenetic relation. Ann Intern Med 88:45, 1978.
polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg 166. Danon F, Bussel A, Perol Y: Immunoglobulines monoclonales infections a cytomegalo-
Psychiatry 59:243, 1995. virus et hémopathies malignes. Ann Immunol (Paris) 128A:83, 1977.
132. Lee YC, Came N, Schwarer A, Day B: Autologous peripheral blood stem cell transplan- 167. Papadopoulos NM, Lane HC, Costello R, et al: Oligoclonal immunoglobulins in
tation for peripheral neuropathy secondary to monoclonal gammopathy of unknown patients with the acquired immunodeficiency syndrome. Clin Immunol Immunopathol
significance. Bone Marrow Transplant 30:53, 2002. 35:43, 1985.

Kaushansky_chapter 106_p1721-1732.indd 1729 9/21/15 12:40 PM